Natera receives FDA breakthrough designation; stock pre-market at EUR 359.20
Published on 10/12/2026 at 07:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Natera received FDA Breakthrough Device designation for its MCED assay.
- The assay analyzes cell-free DNA to screen for multiple cancers.
- Natera stock was at EUR 359.20 pre-market at Lang & Schwarz.
Natera announced on October 9, 2026, that the U.S. Food and Drug Administration had granted Breakthrough Device designation to its multi-cancer early detection assay. The stock was at EUR 359.20 at Lang & Schwarz at 7:37 a.m. CEST on October 12, 2026.
Pre-market indication
Lang & Schwarz quoted Natera at EUR 359.20 before the Xetra open. The bid was EUR 357.10 and the ask was EUR 361.30. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Natera stock.
FDA designation
In its company release, Natera said the assay analyzes cell-free DNA to screen for multiple cancers. The FDA considered data from 12 cancer types, including sensitivity, specificity and cancer signal origin performance, when granting the designation.
Market context: Market report Nasdaq Composite.
